Urinary peptide panel for prognostic assessment of bladder cancer relapse

Non-invasive tools stratifying bladder cancer (BC) patients according to the risk of relapse are urgently needed to guide clinical intervention. As a follow-up to the previously published study on CE-MS-based urinary biomarkers for BC detection and recurrence monitoring, we expanded the investigatio...

Full description

Saved in:
Bibliographic Details
Published in:Scientific reports 2019-05, Vol.9 (1), p.7635-7635, Article 7635
Main Authors: Krochmal, Magdalena, van Kessel, Kim E. M., Zwarthoff, Ellen C., Belczacka, Iwona, Pejchinovski, Martin, Vlahou, Antonia, Mischak, Harald, Frantzi, Maria
Format: Article
Language:English
Subjects:
692/4017
692/4025/1334
692/53/2422
82/29
82/58
Aged
Biomarkers, Tumor - urine
Bladder cancer
Female
Humanities and Social Sciences
Humans
Male
Middle Aged
multidisciplinary
Peptides
Peptides - urine
Recurrence
Risk assessment
Science
Science (multidisciplinary)
Urinary Bladder Neoplasms - pathology
Urinary Bladder Neoplasms - urine
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c522t-4eaa2e2baaf7dccc9e52515b48e0898b3665f970ee145e863a480450622745953
cites cdi_FETCH-LOGICAL-c522t-4eaa2e2baaf7dccc9e52515b48e0898b3665f970ee145e863a480450622745953
container_end_page 7635
container_issue 1
container_start_page 7635
container_title Scientific reports
container_volume 9
creator Krochmal, Magdalena
van Kessel, Kim E. M.
Zwarthoff, Ellen C.
Belczacka, Iwona
Pejchinovski, Martin
Vlahou, Antonia
Mischak, Harald
Frantzi, Maria
description Non-invasive tools stratifying bladder cancer (BC) patients according to the risk of relapse are urgently needed to guide clinical intervention. As a follow-up to the previously published study on CE-MS-based urinary biomarkers for BC detection and recurrence monitoring, we expanded the investigation towards BC patients with longitudinal data. Profiling datasets of BC patients with follow-up information regarding the relapse status were investigated. The peptidomics dataset (n = 98) was split into training and test set. Cox regression was utilized for feature selection in the training set. Investigation of the entire training set at the single peptide level revealed 36 peptides being strong independent prognostic markers of disease relapse. Those features were further integrated into a Random Forest-based model evaluating the risk of relapse for BC patients. Performance of the model was assessed in the test cohort, showing high significance in BC relapse prognosis [HR = 5.76, p-value = 0.0001, c-index = 0.64]. Urinary peptide profiles integrated into a prognostic model allow for quantitative risk assessment of BC relapse highlighting the need for its incorporation in prospective studies to establish its value in the clinical management of BC.
doi_str_mv 10.1038/s41598-019-44129-y
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6529475</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2228656093</sourcerecordid><originalsourceid>FETCH-LOGICAL-c522t-4eaa2e2baaf7dccc9e52515b48e0898b3665f970ee145e863a480450622745953</originalsourceid><addsrcrecordid>eNp9kctOwzAQRS0Eggr6AyxQJDZsAvbETuwNEqp4VKrEBtaW40xKUBoHO0Xq3-PSUh4LvBlLc-Z6ri8hp4xeMprJq8CZUDKlTKWcM1Dpao-MgHKRQgaw_-N-RMYhvNJ4BCjO1CE5yhhjnDIYkemzbzrjV0mP_dBUmPSmwzapnU967-adC0NjExMChrDAbkhcnZStqSr0iTWdjcVja_qAJ-SgNm3A8bYek-e726fJQzp7vJ9ObmapFQBDytEYQCiNqYvKWqtQgGCi5BKpVLLM8lzUqqCIjAuUeWa4jE5oDlBwoUR2TK43uv2yXGBl41LetLr3zSL60M40-nena1703L3rfG2_WAtcbAW8e1tiGPSiCRbbNjp3y6AhfhotJMg1ev4HfXVL30V7kQKZi5yqLFKwoax3IXisd8swqtdh6U1YOoalP8PSqzh09tPGbuQrmghkGyDEVjdH__32P7IfObGgNA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2228656093</pqid></control><display><type>article</type><title>Urinary peptide panel for prognostic assessment of bladder cancer relapse</title><source>Publicly Available Content Database</source><source>PubMed Central(OpenAccess)</source><source>Free Full-Text Journals in Chemistry</source><source>Springer Nature - nature.com Journals - Fully Open Access</source><creator>Krochmal, Magdalena ; van Kessel, Kim E. M. ; Zwarthoff, Ellen C. ; Belczacka, Iwona ; Pejchinovski, Martin ; Vlahou, Antonia ; Mischak, Harald ; Frantzi, Maria</creator><creatorcontrib>Krochmal, Magdalena ; van Kessel, Kim E. M. ; Zwarthoff, Ellen C. ; Belczacka, Iwona ; Pejchinovski, Martin ; Vlahou, Antonia ; Mischak, Harald ; Frantzi, Maria</creatorcontrib><description>Non-invasive tools stratifying bladder cancer (BC) patients according to the risk of relapse are urgently needed to guide clinical intervention. As a follow-up to the previously published study on CE-MS-based urinary biomarkers for BC detection and recurrence monitoring, we expanded the investigation towards BC patients with longitudinal data. Profiling datasets of BC patients with follow-up information regarding the relapse status were investigated. The peptidomics dataset (n = 98) was split into training and test set. Cox regression was utilized for feature selection in the training set. Investigation of the entire training set at the single peptide level revealed 36 peptides being strong independent prognostic markers of disease relapse. Those features were further integrated into a Random Forest-based model evaluating the risk of relapse for BC patients. Performance of the model was assessed in the test cohort, showing high significance in BC relapse prognosis [HR = 5.76, p-value = 0.0001, c-index = 0.64]. Urinary peptide profiles integrated into a prognostic model allow for quantitative risk assessment of BC relapse highlighting the need for its incorporation in prospective studies to establish its value in the clinical management of BC.</description><identifier>ISSN: 2045-2322</identifier><identifier>EISSN: 2045-2322</identifier><identifier>DOI: 10.1038/s41598-019-44129-y</identifier><identifier>PMID: 31114012</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>692/4017 ; 692/4025/1334 ; 692/53/2422 ; 82/29 ; 82/58 ; Aged ; Biomarkers, Tumor - urine ; Bladder cancer ; Female ; Humanities and Social Sciences ; Humans ; Male ; Middle Aged ; multidisciplinary ; Peptides ; Peptides - urine ; Recurrence ; Risk assessment ; Science ; Science (multidisciplinary) ; Urinary Bladder Neoplasms - pathology ; Urinary Bladder Neoplasms - urine</subject><ispartof>Scientific reports, 2019-05, Vol.9 (1), p.7635-7635, Article 7635</ispartof><rights>The Author(s) 2019</rights><rights>The Author(s) 2019. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c522t-4eaa2e2baaf7dccc9e52515b48e0898b3665f970ee145e863a480450622745953</citedby><cites>FETCH-LOGICAL-c522t-4eaa2e2baaf7dccc9e52515b48e0898b3665f970ee145e863a480450622745953</cites><orcidid>0000-0002-7167-8463</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2228656093/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2228656093?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31114012$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Krochmal, Magdalena</creatorcontrib><creatorcontrib>van Kessel, Kim E. M.</creatorcontrib><creatorcontrib>Zwarthoff, Ellen C.</creatorcontrib><creatorcontrib>Belczacka, Iwona</creatorcontrib><creatorcontrib>Pejchinovski, Martin</creatorcontrib><creatorcontrib>Vlahou, Antonia</creatorcontrib><creatorcontrib>Mischak, Harald</creatorcontrib><creatorcontrib>Frantzi, Maria</creatorcontrib><title>Urinary peptide panel for prognostic assessment of bladder cancer relapse</title><title>Scientific reports</title><addtitle>Sci Rep</addtitle><addtitle>Sci Rep</addtitle><description>Non-invasive tools stratifying bladder cancer (BC) patients according to the risk of relapse are urgently needed to guide clinical intervention. As a follow-up to the previously published study on CE-MS-based urinary biomarkers for BC detection and recurrence monitoring, we expanded the investigation towards BC patients with longitudinal data. Profiling datasets of BC patients with follow-up information regarding the relapse status were investigated. The peptidomics dataset (n = 98) was split into training and test set. Cox regression was utilized for feature selection in the training set. Investigation of the entire training set at the single peptide level revealed 36 peptides being strong independent prognostic markers of disease relapse. Those features were further integrated into a Random Forest-based model evaluating the risk of relapse for BC patients. Performance of the model was assessed in the test cohort, showing high significance in BC relapse prognosis [HR = 5.76, p-value = 0.0001, c-index = 0.64]. Urinary peptide profiles integrated into a prognostic model allow for quantitative risk assessment of BC relapse highlighting the need for its incorporation in prospective studies to establish its value in the clinical management of BC.</description><subject>692/4017</subject><subject>692/4025/1334</subject><subject>692/53/2422</subject><subject>82/29</subject><subject>82/58</subject><subject>Aged</subject><subject>Biomarkers, Tumor - urine</subject><subject>Bladder cancer</subject><subject>Female</subject><subject>Humanities and Social Sciences</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>multidisciplinary</subject><subject>Peptides</subject><subject>Peptides - urine</subject><subject>Recurrence</subject><subject>Risk assessment</subject><subject>Science</subject><subject>Science (multidisciplinary)</subject><subject>Urinary Bladder Neoplasms - pathology</subject><subject>Urinary Bladder Neoplasms - urine</subject><issn>2045-2322</issn><issn>2045-2322</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><recordid>eNp9kctOwzAQRS0Eggr6AyxQJDZsAvbETuwNEqp4VKrEBtaW40xKUBoHO0Xq3-PSUh4LvBlLc-Z6ri8hp4xeMprJq8CZUDKlTKWcM1Dpao-MgHKRQgaw_-N-RMYhvNJ4BCjO1CE5yhhjnDIYkemzbzrjV0mP_dBUmPSmwzapnU967-adC0NjExMChrDAbkhcnZStqSr0iTWdjcVja_qAJ-SgNm3A8bYek-e726fJQzp7vJ9ObmapFQBDytEYQCiNqYvKWqtQgGCi5BKpVLLM8lzUqqCIjAuUeWa4jE5oDlBwoUR2TK43uv2yXGBl41LetLr3zSL60M40-nena1703L3rfG2_WAtcbAW8e1tiGPSiCRbbNjp3y6AhfhotJMg1ev4HfXVL30V7kQKZi5yqLFKwoax3IXisd8swqtdh6U1YOoalP8PSqzh09tPGbuQrmghkGyDEVjdH__32P7IfObGgNA</recordid><startdate>20190521</startdate><enddate>20190521</enddate><creator>Krochmal, Magdalena</creator><creator>van Kessel, Kim E. M.</creator><creator>Zwarthoff, Ellen C.</creator><creator>Belczacka, Iwona</creator><creator>Pejchinovski, Martin</creator><creator>Vlahou, Antonia</creator><creator>Mischak, Harald</creator><creator>Frantzi, Maria</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>88I</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-7167-8463</orcidid></search><sort><creationdate>20190521</creationdate><title>Urinary peptide panel for prognostic assessment of bladder cancer relapse</title><author>Krochmal, Magdalena ; van Kessel, Kim E. M. ; Zwarthoff, Ellen C. ; Belczacka, Iwona ; Pejchinovski, Martin ; Vlahou, Antonia ; Mischak, Harald ; Frantzi, Maria</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c522t-4eaa2e2baaf7dccc9e52515b48e0898b3665f970ee145e863a480450622745953</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>692/4017</topic><topic>692/4025/1334</topic><topic>692/53/2422</topic><topic>82/29</topic><topic>82/58</topic><topic>Aged</topic><topic>Biomarkers, Tumor - urine</topic><topic>Bladder cancer</topic><topic>Female</topic><topic>Humanities and Social Sciences</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>multidisciplinary</topic><topic>Peptides</topic><topic>Peptides - urine</topic><topic>Recurrence</topic><topic>Risk assessment</topic><topic>Science</topic><topic>Science (multidisciplinary)</topic><topic>Urinary Bladder Neoplasms - pathology</topic><topic>Urinary Bladder Neoplasms - urine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Krochmal, Magdalena</creatorcontrib><creatorcontrib>van Kessel, Kim E. M.</creatorcontrib><creatorcontrib>Zwarthoff, Ellen C.</creatorcontrib><creatorcontrib>Belczacka, Iwona</creatorcontrib><creatorcontrib>Pejchinovski, Martin</creatorcontrib><creatorcontrib>Vlahou, Antonia</creatorcontrib><creatorcontrib>Mischak, Harald</creatorcontrib><creatorcontrib>Frantzi, Maria</creatorcontrib><collection>SpringerOpen</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Health and Medical</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection (Proquest) (PQ_SDU_P3)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest Science Journals</collection><collection>ProQuest Biological Science Journals</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Scientific reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Krochmal, Magdalena</au><au>van Kessel, Kim E. M.</au><au>Zwarthoff, Ellen C.</au><au>Belczacka, Iwona</au><au>Pejchinovski, Martin</au><au>Vlahou, Antonia</au><au>Mischak, Harald</au><au>Frantzi, Maria</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Urinary peptide panel for prognostic assessment of bladder cancer relapse</atitle><jtitle>Scientific reports</jtitle><stitle>Sci Rep</stitle><addtitle>Sci Rep</addtitle><date>2019-05-21</date><risdate>2019</risdate><volume>9</volume><issue>1</issue><spage>7635</spage><epage>7635</epage><pages>7635-7635</pages><artnum>7635</artnum><issn>2045-2322</issn><eissn>2045-2322</eissn><abstract>Non-invasive tools stratifying bladder cancer (BC) patients according to the risk of relapse are urgently needed to guide clinical intervention. As a follow-up to the previously published study on CE-MS-based urinary biomarkers for BC detection and recurrence monitoring, we expanded the investigation towards BC patients with longitudinal data. Profiling datasets of BC patients with follow-up information regarding the relapse status were investigated. The peptidomics dataset (n = 98) was split into training and test set. Cox regression was utilized for feature selection in the training set. Investigation of the entire training set at the single peptide level revealed 36 peptides being strong independent prognostic markers of disease relapse. Those features were further integrated into a Random Forest-based model evaluating the risk of relapse for BC patients. Performance of the model was assessed in the test cohort, showing high significance in BC relapse prognosis [HR = 5.76, p-value = 0.0001, c-index = 0.64]. Urinary peptide profiles integrated into a prognostic model allow for quantitative risk assessment of BC relapse highlighting the need for its incorporation in prospective studies to establish its value in the clinical management of BC.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>31114012</pmid><doi>10.1038/s41598-019-44129-y</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0002-7167-8463</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2045-2322
ispartof Scientific reports, 2019-05, Vol.9 (1), p.7635-7635, Article 7635
issn 2045-2322
2045-2322
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6529475
source Publicly Available Content Database; PubMed Central(OpenAccess); Free Full-Text Journals in Chemistry; Springer Nature - nature.com Journals - Fully Open Access
subjects 692/4017
692/4025/1334
692/53/2422
82/29
82/58
Aged
Biomarkers, Tumor - urine
Bladder cancer
Female
Humanities and Social Sciences
Humans
Male
Middle Aged
multidisciplinary
Peptides
Peptides - urine
Recurrence
Risk assessment
Science
Science (multidisciplinary)
Urinary Bladder Neoplasms - pathology
Urinary Bladder Neoplasms - urine
title Urinary peptide panel for prognostic assessment of bladder cancer relapse
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T00%3A34%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Urinary%20peptide%20panel%20for%20prognostic%20assessment%20of%20bladder%20cancer%20relapse&rft.jtitle=Scientific%20reports&rft.au=Krochmal,%20Magdalena&rft.date=2019-05-21&rft.volume=9&rft.issue=1&rft.spage=7635&rft.epage=7635&rft.pages=7635-7635&rft.artnum=7635&rft.issn=2045-2322&rft.eissn=2045-2322&rft_id=info:doi/10.1038/s41598-019-44129-y&rft_dat=%3Cproquest_pubme%3E2228656093%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c522t-4eaa2e2baaf7dccc9e52515b48e0898b3665f970ee145e863a480450622745953%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2228656093&rft_id=info:pmid/31114012&rfr_iscdi=true